SYN Synthetic Biologics

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Company profile

Steven A. Shallcross
Fiscal year end
Former names
IRS number

SYN stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


4 Mar 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.23M 6.23M 6.23M 6.23M 6.23M 6.23M
Cash burn (monthly) (positive/no burn) 734.83K 710.67K 846.67K 1.04M 1.01M
Cash used (since last report) n/a 2.62M 2.53M 3.02M 3.72M 3.61M
Cash remaining n/a 3.61M 3.69M 3.21M 2.51M 2.61M
Runway (months of cash) n/a 4.9 5.2 3.8 2.4 2.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Dec 20 Steven A Shallcross Stock Options Common Stock Grant Aquire A No No 0.417 450,000 187.65K 450,000
30 Dec 20 John J Monahan Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000
30 Dec 20 Wolf Jeffrey Alan Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000
30 Dec 20 Kraws Jeffrey J Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

5.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 24 23 +4.3%
Opened positions 5 0 NEW
Closed positions 4 6 -33.3%
Increased positions 5 5
Reduced positions 3 4 -25.0%
13F shares
Current Prev Q Change
Total value 2.72M 651K +317.2%
Total shares 7.16M 1.37M +423.4%
Total puts 0 0
Total calls 0 225K EXIT
Total put/call ratio
Largest owners
Shares Value Change
Hudson Bay Capital Management 2.22M $850K NEW
Custodian Ventures 1.96M $728K NEW
Renaissance Technologies 1.24M $474K +44.0%
Iroquois Capital Management 1.13M $433K NEW
Fisher Asset Management 125.7K $48K +108.4%
Bridgeway Capital Management 109.3K $42K 0.0%
VIRT Virtu Financial 104.39K $40K NEW
Acadian Asset Management 72.79K $28K 0.0%
Blair William & Co 54.54K $21K +3.2%
BLK Blackrock 38.21K $14K 0.0%
Largest transactions
Shares Bought/sold Change
Hudson Bay Capital Management 2.22M +2.22M NEW
Custodian Ventures 1.96M +1.96M NEW
Iroquois Capital Management 1.13M +1.13M NEW
Renaissance Technologies 1.24M +378K +44.0%
VIRT Virtu Financial 104.39K +104.39K NEW
Vanguard 36.39K -87K -70.5%
Fisher Asset Management 125.7K +65.37K +108.4%
Susquehanna International 15.71K +15.71K NEW
NTRS Northern Trust 13.65K -14.86K -52.1%
Tower Research Capital 14.8K +14.7K +14695.0%

Financial report summary

Content analysis
H.S. sophomore Avg
New words: abated, absenteeism, adequacy, AGP, Alameda, altogether, ANIX, Anixa, Artugen, ascending, AVGN, Baylor, biochemistry, Bordetella, CA, called, cap, carryback, celiac, Cellix, chart, clause, cleaning, climate, closure, contradictory, convene, curb, Deinove, discernable, disconnected, downturn, Dublin, dysfunction, economy, evolution, fatty, feasible, fire, flexibility, flexible, footnote, frailty, furlough, globe, heightening, Hodin, Houston, ill, inconsistent, incorrect, inflammatory, inflated, instability, Instructor, Ireland, John, leader, lifespan, MAD, McMaster, meantime, merged, Meridian, MGH, mice, Mitsubishi, Monahan, NAFLD, nationwide, NJ, noncompliance, Nutley, outbreak, overstating, political, predominantly, prespecified, proper, PTC, rapid, reliance, runway, SAD, sector, shipping, sick, skill, slowdown, social, Somatix, squeeze, steadily, stemming, strain, streamlined, subtopic, Surgery, sweeping, Tanabe, telemedicine, temporarily, terrorism, transmission, transport, Triton, TX, unblinded, underway, unique, visit, war, weather, Wuhan
Removed: AB, Abbreviated, ABR, acquirer, adaptive, added, Addendum, adolescence, adulthood, Allergan, alternating, amend, analyte, ANDA, annualized, anolo, antimethanogenic, anytime, applicant, Ardelyx, Assembly, AUC, Avenue, avoiding, behavior, belonging, bioequivalent, Black, branded, byM, calendar, California, career, certify, challenged, CIC, classification, clear, clinically, COBRA, commute, competitor, composite, composition, compounded, confident, considerably, constitute, consummated, consummation, contendere, converting, conviction, copy, correlation, crime, CSBM, curable, cured, depleting, depletion, dereliction, detectable, developer, discouraging, discovered, dishonesty, disorder, distance, divergent, Eagle, education, educational, EGRX, embezzlement, entrusted, Equivalence, execute, extraordinary, fault, FDCA, feedback, felony, fiduciary, filer, forC, Forest, forward, functional, gas, GlobalData, harassment, identifiedC, idiopathic, importance, incorporating, infringed, inhibiting, inhibition, innovation, innovative, innovator, insubordination, insulin, intending, invalid, inverse, invest, Ironwood, lactulose, lifted, lipid, lowered, lumen, marketer, mclean, meaningful, measurable, Meda, men, metabolite, Mevacor, misappropriation, MitsubishiTanabe, mixed, moiety, moral, movement, notify, observed, ofC, ofClostridium, Orange, overproduction, owner, paragraph, parenteral, participated, payroll, Pennsylvania, perception, pertussisinfection, PK, played, plea, ppm, precise, predominant, preferential, prepared, prescribe, prescribed, producing, promoted, proscribed, pursuit, ranking, ratably, ratio, referenced, Reincorporation, relocation, relying, remeasured, represented, responder, Rider, risky, rollover, SBM, score, Scott, screened, separation, shareholder, shortage, situated, Squibb, statistically, Stephen, stomach, struggled, sue, Supplementary, surviving, sustainability, Symptom, symptomatic, takeover, targeting, Tariff, technological, thatB, theB, theC, thereon, toC, top, transition, trough, turpitude, undetectable, unenforceable, unsubtyped, unused, USPTO, validation, vitro, withBordetella, withC, women, workplace, worst, ZIOPHARM